N2-(1-(1-(2-fluoroethyl)piperidin-4-yl)-5-methyl-1H-pyrazol-4-yl)-N4-methyl-5-(trifluoromethyl)pyrimidin-2,4-diamine | 1374827-61-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N2-(1-(1-(2-fluoroethyl)piperidin-4-yl)-5-methyl-1H-pyrazol-4-yl)-N4-methyl-5-(trifluoromethyl)pyrimidin-2,4-diamine
• 英文别名: N2-(1-(1-(2-fluoroethyl)piperidin-4-yl)-5-methyl-1H-pyrazol-4-yl)-N4-methyl-5-(trifluoromethyl)pyrimidine-2,4-diamine；2-N-[1-[1-(2-fluoroethyl)piperidin-4-yl]-5-methylpyrazol-4-yl]-4-N-methyl-5-(trifluoromethyl)pyrimidine-2,4-diamine
• CAS: 1374827-61-8
• 化学式: C₁₇H₂₃F₄N₇
• 分子量: 401.41
• InChiKey: YJUWLJLTEPZWBY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  70.9
• 氢给体数：
  2
• 氢受体数：
  10

文献信息

• [EN] PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS<br/>[FR] DÉRIVÉS DE PYRAZOLE AMINOPYRIMIDINE EN TANT QUE MODULATEURS DU LRRK2
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012062783A1

  公开（公告）日：2012-05-18

  Compounds of the formula (I), or pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.

  化合物的结构式（I）或其药用盐，其中X，R1，R2，R3，R4和R5如本文所定义。还公开了制备这些化合物的方法，并将这些化合物用于治疗与LRRK2受体相关的疾病，如帕金森病。
• [EN] FLUORINE-18 AND CARBON-11 LABELED RADIOLIGANDS FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING FOR LRRK2<br/>[FR] RADIOLIGANDS MARQUÉS PAR LE FLUOR 18 ET LE CARBONE 11 POUR UNE IMAGERIE PAR TOMOGRAPHIE PAR ÉMISSION DE POSITONS (PET) POUR LRRK2
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013079496A1

  公开（公告）日：2013-06-06

  A method for positron emission tomography (PET) imaging of LRRK2 in the tissue of a subject, the method comprising: administering a compound of formula (I), formula (II) or formula (III), or a pharmaceutically acceptable salt thereof to the subject, wherein the compound includes at least one C11 or F18 label thereon; allowing the compound to penetrate into the tissue of the subject; and collecting a PET image of the CNS or brain tissue of the subject.

  一种用于正电子发射断层扫描（PET）成像受试者组织中的LRRK2的方法，包括：向受试者注射式(I)、式(II)或式(III)的化合物或其药学上可接受的盐，其中该化合物上至少有一个C11或F18标记；让该化合物渗透到受试者的组织中；并收集受试者中枢神经系统或脑组织的PET图像。
• PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS
  申请人：Baker-Glenn Charles

  公开号：US20120157427A1

  公开（公告）日：2012-06-21

  Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein X, R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.

  化合物I的公式为：或其药学上可接受的盐，其中X，R1，R2，R3，R4和R5如本文所定义。还公开了制备该化合物的方法以及使用该化合物治疗与LRRK2受体相关的疾病，如帕金森病的方法。
• FLUORINE-18 AND CARBON-11 LABELED RADIOLIGANDS FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING FOR LRRK2
  申请人：Genentech, Inc.

  公开号：US20130156700A1

  公开（公告）日：2013-06-20

  A method for positron emission tomography (PET) imaging of LRRK2 in tissue of a subject, the method comprising: administering a compound of formula I, formula II or formula III, or a pharmaceutically acceptable salt thereof to the subject, wherein the compound includes at least one C 11 or F 18 label thereon; allowing the compound to penetrate into the tissue of the subject; and collecting a PET image of the CNS or brain tissue of the subject

  一种用于在受试者组织中进行LRRK2正电子发射断层扫描（PET）成像的方法，包括：向受试者给予公式I、公式II或公式III的化合物或其药学上可接受的盐，其中该化合物上至少有一个C11或F18标记；使该化合物渗入受试者的组织中；并收集受试者的中枢神经系统或脑组织的PET图像。
• ASSAYS AND BIOMARKERS FOR LRRK2
  申请人：Genentech, Inc.

  公开号：EP2646819A1

  公开（公告）日：2013-10-09